GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » Cyclically Adjusted PS Ratio

Elite Pharmaceuticals (STU:ETF) Cyclically Adjusted PS Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Elite Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Elite Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.30 5.34 4.49 2.05 1.43

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 1.43 1.80 4.17 5.96

Competitive Comparison of Elite Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elite Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Elite Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Elite Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Elite Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Elite Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.014/129.4194*129.4194
=0.014

Current CPI (Dec. 2023) = 129.4194.

Elite Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.001 99.695 0.001
201406 0.001 100.560 0.001
201409 0.001 100.428 0.001
201412 0.001 99.070 0.001
201503 0.001 99.621 0.001
201506 0.002 100.684 0.003
201509 0.003 100.392 0.004
201512 0.003 99.792 0.004
201603 0.007 100.470 0.009
201606 0.004 101.688 0.005
201609 0.003 101.861 0.004
201612 0.002 101.863 0.003
201703 0.001 102.862 0.001
201706 0.002 103.349 0.003
201709 0.002 104.136 0.002
201712 0.003 104.011 0.004
201803 0.002 105.290 0.002
201806 0.002 106.317 0.002
201809 0.001 106.507 0.001
201812 0.003 105.998 0.004
201903 0.001 107.251 0.001
201906 0.004 108.070 0.005
201909 0.005 108.329 0.006
201912 0.005 108.420 0.006
202003 0.003 108.902 0.004
202006 0.007 108.767 0.008
202009 0.007 109.815 0.008
202012 0.005 109.897 0.006
202103 0.004 111.754 0.005
202106 0.006 114.631 0.007
202109 0.007 115.734 0.008
202112 0.008 117.630 0.009
202203 0.007 121.301 0.007
202206 0.007 125.017 0.007
202209 0.009 125.227 0.009
202212 0.009 125.222 0.009
202303 0.008 127.348 0.008
202306 0.008 128.729 0.008
202309 0.013 129.860 0.013
202312 0.014 129.419 0.014

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Elite Pharmaceuticals  (STU:ETF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Elite Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (STU:ETF) Business Description

Traded in Other Exchanges
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines